Mgmt and msh2 immunohistochemistry status identifies a pituitary tumour subgroup with excellent progression free survival response to temozolomide: Flatiron seeks to minimize overlap. As such, the reported safety profile, and the risk benefit assessment of the current submission, fully encompasses the real world use of the paclitaxel premedications.”
Trailblazers Monica Pearson, Dr. Lonnie Johnson and the Stanleys
(f) the hr of pfs in studies using tkis or tkis plus icis.
The resubmission acknowledged that the assumption of no wastage may not be consistent with the current pbac guidelines, however considered that it remained consistent.
